Clinical Trials Browser

Stomach Neoplasms

Advanced Gastric Cancer

Neoplasm Metastasis

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung

Stage IV Gastric Cancer With Metastasis

Advanced Gastric Adenocarcinoma

HER2-positive

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Pancreatic Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Metastatic Gastric Adenocarcinoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Carcinoma, Pancreatic Ductal

Pancreatic Neoplasms

Stomach Neoplasms

Pancreatic Neoplasms

Advanced NSCLC With EGFR Mutation

Pancreatic Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Colorectal Neoplasms

Stomach Neoplasms

Lung Neoplasms, Radiation Injuries

Borderline Resectable Pancreatic Cancer

Locally Advanced Pancreatic Cancer

Stomach Neoplasms

Advanced Pancreatic Cancer

Advanced Biliary Tract Cancer

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

HER-2 Negatived Gastric Cancer

Biliary Tract Neoplasms

Pancreatic Neoplasms

Gastric Cancer With Positive Exfoliative Cancer Cells

Head and Neck Neoplasms

Advanced Pancreatic Cancer

Pancreatic Neoplasms

Clinical Trials

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

LOTS

SVOSA

To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer

A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis

The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

NAPAN

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

SBRTLCES

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer

Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Y-HR2017-025

ASPC

ASAGPAC

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer